Half-Life & Pharmacokinetics
Technical explainer hub focused on peptide half-life, exposure timing, and pharmacokinetic interpretation.
Search demand shows repeated low-volume but high-intent questions around half-life and timing. This hub gives those questions a central, linkable home.
What does peptide half-life actually change in practice?
How do short-acting and long-acting peptides differ in protocol design?
What limits should readers understand when comparing PK claims online?
Featured PK Guides
Peptide Half-Life Explained: Why Timing Changes Everything
Practical guide to peptide half-life, pharmacokinetic assumptions, and why timing claims differ across protocols.
SS-31 / Elamipretide (Forzinity): Mitochondrial Peptide, FDA Approved 2025
SS-31 (elamipretide, brand name Forzinity) became the first FDA-approved mitochondria-targeting peptide in September 2025, cleared for Barth syndrome. This guide covers the cardiolipin mechanism, the TAZPOWER trial, and what approval means for broader longevity research interest.
Growth Hormone Releasing Peptides: Mechanisms & Research
Comprehensive analysis of GHRPs and GHRHs, including mechanism-level differences and evidence gaps.
IGF-1 DES: Half-Life, Dose Charts, and Research Interpretation
IGF-1 DES explainer focused on half-life, dose charts, and evidence-aware interpretation.
Fragment 176-191: Dosage, Side Effects, Half-Life, and Common Claims
Educational guide to Fragment 176-191 covering the questions users actually search: dosage, half-life, side effects, and mechanism.
Peptides With Strong PK Intent
IGF-1 DES
20-30 minutes half-life context
SS-31
Short half-life context
LL-37
Short half-life context
Fragment 176-191
30 minutes half-life context
MOTS-c
Short half-life context